867366-91-4

Usage

Uses

Used in Pharmaceutical Research:
3-Bromo-5-methoxy benzonitrile is utilized as a key intermediate in the synthesis of new drugs, contributing to the advancement of pharmaceutical chemistry. Its unique structure and reactivity make it a valuable component in the development of innovative therapeutic agents.
Used in Agrochemical Development:
In the agrochemical industry, 3-Bromo-5-methoxy benzonitrile serves as a crucial building block for the creation of novel agrochemicals. Its application in this field aids in the development of more effective and environmentally friendly products for agricultural use.
Used in Organic Synthesis:
3-Bromo-5-methoxy benzonitrile is employed as a versatile reagent in organic synthesis, enabling the production of a wide range of chemical compounds. Its unique properties facilitate various chemical reactions, broadening the scope of synthetic chemistry.

InChI:InChI=1S/C8H6BrNO/c1-11-8-3-6(5-10)2-7(9)4-8/h2-4H,1H3

Upstream product

• 124-41-4 sodium methylate 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 401797-04-4 2-(3-bromo-5-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 262450-65-7 3-bromo-5-methoxybenzaldehyde 
• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 262450-64-6 (3-bromo-5-methoxyphenyl)methanol 
• 2398-37-0 3-methoxyphenyl bromide 
• 867366-90-3 3-bromo-5-methoxy-benzaldehyde oxime 

Downstream Products

• 770718-92-8 3-bromo-5-hydroxybenzonitrile 
• 1177558-46-1 (3-bromo-5-methoxyphenyl)methanamine 
• 1404169-12-5 N-(2,6-diisopropylphenyl)-5-methoxy-[1,1'-biphenyl]-3-carboximidamide 
• 1395093-28-3 1-(2,6-diisopropylphenyl)-2-(5-methoxy-[1,1'-biphenyl]-3-yl)-1H-imidazole 
• 1395093-29-4 5-(1-(2,6-diisopropylphenyl)-1H-imidazol-2-yl)-[1,1'-biphenyl]-3-ol 
• 1395093-30-7 2,2'-(oxybis([1,1'-biphenyl]-5,3-diyl))bis(1-(2,6-diisopropylphenyl)-1H-imidazole) 
• 1035266-33-1 3-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzonitrile 
• 1590397-27-5 2-[(4-fluorobenzenesulfonyl)(isopropyl)amino]-N-(5-methoxy-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-26-4 2-[ethyl-(4-fluorobenzenesulfonyl)amino]-N-(5-methoxy-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-25-3 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-(5-methoxy-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1380072-47-8 6-methyl-2-[(3-cyano-5-methoxyphenyl)ethynyl]pyridine 
• 157893-14-6 3-bromo-5-methoxybenzoic acid 

Relevant academic research and scientific papers

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

NOVEL TETRADENTATE PLATINUM COMPLEXES

Novel phosphorescent tetradentate platinum (II) compounds comprising a twisted aryl group are provided. Also provided are novel phosphorescent tetradentate platinum (II) compounds comprising an imidazo[1,2-f]phenanthridine moiety. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime.

Cyanation of arenes via iridium-catalyzed borylation

We report a method to conduct one-pot meta cyanation of arenes by iridium-catalyzed C-H borylation and copper-mediated cyanation of the resulting arylboronate esters. This process relies on a method to conduct the cyanation of arylboronic esters, and conditions for this new transformation are reported. Conditions for the copper-mediated cyanation of arylboronic acids are also reported. By the resulting sequence of borylation and cyanation, 1,3-disubstituted and 1,2,3-trisubstituted arenes and heteroarenes containing halide, ketone, ester, amide, and protected alcohol functionalities are converted to the corresponding meta-substituted aryl nitriles. The utility of this methodology is demonstrated through the conversion of a protected 2,6-disubstituted phenol to 4-cyano-2,6-dimethylphenol, which is an intermediate in the synthesis of the pharmaceutical etravirine. The utility of the method is further demonstrated by the conversion of 3-chloro-5-methylbenzonitrile, produced through the one-pot C-H borylation and cyanation sequence, to the corresponding 3,5-disubstituted aldehydes, ketones, amides, carboxylic acids, tetrazoles, and benzylamines.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease

The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

NOVEL COMPOUNDS

The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.